[Evaluation on the effect of Benazepril for hypertension through postmarketing surveillance].
OBJECTIVE
To evaluate the efficacy and safety of Benazepril used among the essential hypertensives.


METHODS
1 831 essential hypertensive patients aged 35 to 75 were randomly selected from a community and followed for 18 months. The level of blood pressure, status of taking Benazepril and side effects were sequencially collected.


RESULTS
1/3 of the patients had taken antihypertensive drug before the study and the rate of compliance was over 96%. The effective rate of Benazepril was 73.6% at three months and increased to 84.7% at 18 months. Comparing with the baseline data, SBP and DBP declined 10.8 mmHg and 6.7 mmHg respectively. The rate of side effect was 22.7%. Cough was most commonly seen among side effects. The peak of first recording on side effect occurred at three months including 60% of them mild.


CONCLUSIONS
Results showed that Benazepril had good efficacy and safety for the essential hypertension patients in a long-term observation.
Cao
W
W
Department of Epidemiology, Beijing Medical University, Beijing 100083, China.
Li
L
L
Hu
Y
Y
Zhan
S
S
Li
X
X
Li
P
P
Wu
T
T
Li
J
J
Wang
T
T
D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001552:Benzazepines / Q000009:adverse effects / Q000627:therapeutic use*; D002681:China / Q000453:epidemiology; D003371:Cough / Q000139:chemically induced; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001552:Benzazepines; C044946:benazepril